What a dog transmissible tumor can teach us about cancer regression
- 16 May 2018
- journal article
- research article
- Published by Taylor & Francis in Molecular & Cellular Oncology
- Vol. 5 (4) , e1472059
Abstract
The canine transmissible venereal tumor (CTVT) is one of the few clonally transmissible cancers in nature and the only one that fully regresses following treatment with vincristine. The molecular signature of CTVT regression has been described in a recent paper published in Cancer Cell, revealing some fundamental insights into cancer regression.Keywords
Funding Information
- Cancer Research UK (UCL-Centre Development Fund)
This publication has 9 references indexed in Scilit:
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Molecular Signatures of Regression of the Canine Transmissible Venereal TumorCancer Cell, 2018
- Emerging Concepts for Immune Checkpoint Blockade-Based Combination TherapiesCancer Cell, 2018
- A Sixth Modality of Infectious Disease: Contagious Cancer from Devils to Clams and BeyondPLOS Pathogens, 2016
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer AgentsCancer Cell, 2015
- Transmissible Dog Cancer Genome Reveals the Origin and History of an Ancient Cell LineageScience, 2014
- Testing the theory of immune selection in cancers that break the rules of transplantationCancer Immunology, Immunotherapy, 2009
- Clonal Origin and Evolution of a Transmissible CancerCell, 2006
- The Canine Transmissible Venereal Tumor: a Unique Result of Tumor Progression1985